trending Market Intelligence /marketintelligence/en/news-insights/trending/yatCvWzRI5l2XbkzggKuRw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Japan's FUJIFILM takes equity stake in Cynata Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Japan's FUJIFILM takes equity stake in Cynata Therapeutics

Australia's Cynata Therapeutics Ltd. said it executed a license option agreement with Japan's FUJIFILM Corp. to develop and commercialize certain Cynata technology.

As part of the deal, FUJIFILM acquired a A$3.97 million strategic equity stake in Cynata through the purchase of 8,088,403 ordinary Cynata shares. After the transaction closes, FUJIFILM will hold a 10.01% stake in Cynata.

The agreement grants FUJIFILM the option to an exclusive, worldwide licence to market CYP-001, Cynata's lead induced pluripotent stem cell-derived therapeutic mesenchymal stem cell product for graft-versus-host disease. The option is exercisable up to 90 days after a primary evaluation period of Cynata's phase 1 clinical trial in GvHD is completed.

An up-front fee of US$3 million is payable, which, including other potential future milestones, totals over A$60 million in potential one-time payments, along with double-digit royalties on net sales of CYP-001 product. If FUJIFILM exercises the option, it will shoulder future CYP-001 development costs.

The agreement also covers an option to negotiate a license for manufacturing CYP-001 product and certain rights to Cynata's proprietary Cymerus technology for treatment of other diseases.

As of Jan.18, US$1 was equivalent to A$1.32.